Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation
Definitions, descriptions, and summarized evidence for multiple peripheral and transcutaneous electrical stimulation therapies (e.g., PENFS, PNS, PSFS, PES, restorative neurostimulation, scrambler therapy, TENS, TLS, FES) as they relate to pain and rehabilitation indications. Affects providers considering use or authorization of these modalities.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation
Removed language indicating Transcutaneous electrical joint stimulation is not considered medically necessary
Removed language indicating Neuromuscular electrical stimulation (NMES) and functional electrical stimulation (FES) are medically necessary in certain circumstances
Revised language pertaining to medical necessity clinical coverage criteria; removed references to InterQual NCDs for TEJSD and NMES
Added detailed criteria specifying when FES is proven and medically necessary for ambulation rehabilitation after SCI
Added detailed criteria specifying when NMES is proven and medically necessary for disuse atrophy, post-TKA rehabilitation, and improving upper extremity function after stroke
Added language that medical records documentation may be required and what it must contain to assess clinical criteria
Removed HCPCS code E0762 and revised description for HCPCS code E0721
Updated Description of Services, Clinical Evidence, and References sections; archived prior version CS036IN.11
04/01/2026policy revision date
addedFES criteria added
removedHCPCS E0762
multipledistinct therapies described
14 monthslongest follow-up reported
Coverage Criteria and Evidence Summaries
Unproven / Not medically necessary
Unproven / Not medically necessary statements
FES other indications: FES is unproven and not medically necessary due to insufficient evidence of efficacy for treating any other indication not listed above
Hayes and other HTAs report low-quality or inconclusive evidence for many FES applications outside specified SCI ambulation criteria.
NMES other indications: NMES is unproven and not medically necessary due to insufficient evidence of efficacy for treating any condition not meeting the criteria above
Evidence for routine NMES in ICU, COPD outpatient replacement of pulmonary rehab, and many other indications is low quality or inconsistent.
Evidence summaries (informational)
Evidence summaries (informational)
SCI and FES evidence summary: Systematic reviews and cohort studies report that FES/NMES can increase muscle cross-sectional area, lean mass, and aerobic fitness in people with SCI and that hybrid FES cycling improves VO2peak versus controls; however, studies are generally small, heterogeneous, and of variable quality, and Hayes concluded evidence for home-based FES after SCI is insufficient.
These are evidence summaries for informational use.
Evidence summaries by indication
Summarized findings across indications (evidence may support use selectively):
MS — Foot Drop: Low-quality body of evidence shows FES improves walking speed and duration comparably to AFOs and may improve HRQOL measures; further RCTs versus AFOs and longer follow-up are recommended.
Hayes HTA and systematic reviews report modest benefits but limited study quality.
Heart Failure (CHF): Meta-analyses report FES improves peak VO2, 6MWD, and QOL versus control but traditional exercise often yields greater improvements; some RCTs reported reduced HF hospitalizations after short FES programs.
Zeng et al., Wang et al., Kadoglou et al.
ICU / Critically Ill: RCTs in ICU populations are mixed; some report no long-term functional benefit when adding FES/NMES to standard rehab while other meta-analyses show improvements in muscle strength or reduced ventilation time; heterogeneity limits conclusions.
Fossat et al. RCT found no improvement; meta-analyses report variable results.
Cerebral Palsy — NMES
Cerebral palsy — NMES evidence
CP evidence: NMES applied with strengthening, gait training, or during serial casting may improve muscle structure, strength, gait kinematics, and some functional measures in children with spastic CP, but protocols, dosages, and outcome domains vary across studies and overall generalizability is limited.
Reviews and RCTs report promising but heterogeneous results; further research needed.
Stroke — NMES
Cerebrovascular accident (stroke) — NMES evidence
Post-stroke dysphagia: Systematic reviews and many RCTs indicate NMES combined with swallowing therapy can improve swallowing function and related outcomes in post-stroke dysphagia, though heterogeneity and variable study quality are concerns.
Wang et al. meta-analysis of 46 RCTs supports benefit when combined with therapy.
Motor recovery and UE function: NMES alone or combined with mirror therapy, CCFES, or repetitive facilitative exercise shows mixed but sometimes positive effects on walking speed, upper-extremity motor scores and ADLs; benefits are influenced by timing (subacute), severity, and targeted limb.
Systematic reviews and RCTs report variable effect sizes and methodological limitations.
Respiratory — NMES
Respiratory conditions — NMES evidence
COPD on mechanical ventilation: Limited RCTs suggest NMES may improve functional independence and reduce mechanical ventilation time in COPD patients on ventilatory support, but studies are few and heterogeneous.
Gutiérrez-Arias et al. meta-analysis included 4 RCTs (144 adults).
COPD outpatients/rehabilitation: Systematic reviews in stable severe COPD report insufficient evidence that NMES improves peak VO2 or HRQOL compared with usual care and NMES should not replace pulmonary rehabilitation based on current data.
Cochrane and Wu et al. reviews conclude evidence low/very low quality.
Coverage-related evidence summaries
Evidence-based summaries and implications
Respiratory conditions (CF, COPD): NMES shows select physiologic and strength improvements in some respiratory populations (e.g., CF exercise programs), but systematic reviews in COPD report insufficient evidence for HRQOL and peak VO2 benefits and caution that NMES should not replace standard pulmonary rehabilitation.
Donadio et al., Wu et al., Hill et al.
Hospitalized/ICU/postoperative patients: Systematic reviews and some RCTs report mixed effects of NMES on muscle strength and functional outcomes; certain short postoperative NMES protocols mitigated early strength loss in older adults after cardiac surgery, but ICU trials frequently show no durable functional benefit.
Takino et al., Fossat et al., Alqurashi et al.
Swallowing/dysphagia: NMES combined with conventional swallowing therapy can improve swallowing outcomes in post-stroke dysphagia across many RCTs, though heterogeneity of protocols and data quality limit certainty.
Wang et al., Alamer et al.
IFT/IFC — evidence-summary coverage stance
Summary of evidence-based stance derived from systematic reviews, RCTs, and guideline recommendations present in this document portion.
IFT/IFC general conclusions: Systematic reviews and guideline statements indicate inconsistent or insufficient evidence for clinically meaningful benefit of IFT/IFC across musculoskeletal conditions; individual RCTs may show short-term improvements but guideline committees (NICE) recommend against offering IFT for certain indications due to low-quality and inconsistent evidence.
NICE guidance explicitly discourages IFT for knee OA and low back pain in some guidance statements.
MENS/MET — evidence-summary coverage stance
Summary of evidence for microcurrent therapies based on small RCTs and meta-analyses included in this document portion.
MENS/MET general conclusions: Available evidence for microcurrent therapies (MENS/MET) consists of small RCTs and limited meta-analyses showing modest short-term pain reduction in select conditions (e.g., masticatory myofascial pain, acute knee pain), but studies are small, heterogeneous, and lack long-term follow-up; further robust RCTs are needed before broad conclusions can be made.
Bavarian et al., Ranker et al., Curtis et al.
Evidence considerations (informational)
Summary of evidence-based considerations derived from included studies and guidelines
TEAS perioperative evidence: Systematic reviews of TEAS report reductions in short-term postoperative pain and opioid consumption within the first 24 hours, though effects are often small and heterogeneity across trials is high.
Tan et al., Zhang et al.
PENS musculoskeletal/neuropathic pain evidence: Systematic reviews indicate small-to-moderate immediate or short-term effects of PENS on pain and pressure pain thresholds, but long-term benefit and clinical significance remain unclear; guideline positions vary by indication.
Beltran-Alacreu et al., Rodriguez Lagos et al., NICE.
MENS evidence: Small trials suggest potential short-term benefits for pain or function in select populations, but methodological limitations and small samples preclude strong recommendations.
Ranker et al., Kwon et al.
Coverage considerations by indication
Coverage considerations informed by evidence and guidelines for specific indications
Guideline-based stance: Guideline and HTA positions vary by indication: NICE discourages PENS/IFT/TENS for LBP; AAN/AANEM/AAPMR consider PENS for PDN; AAOS rates PENS as Limited for knee OA due to feasibility and training considerations.
Guideline language varies by indication and evidence quality.
PENFS for pediatric functional GI disorders: Studies of auricular PENFS in adolescents used 4-week treatment courses and typically enrolled patients who had failed multiple pharmacologic therapies; consider coverage when documentation shows prior medication failures and planned treatment matches studied protocols.
Kovacic, Santucci, Chogle studies use 4-week protocols.
PNS for postoperative or chronic orthopedic pain: Randomized placebo-controlled PNS trials (eg, post-TKA) and prospective series for medial branch PNS used defined treatment durations (eg, 60-day courses) and enrolled patients refractory to conservative care; consider coverage when patient selection, trial duration, and documentation align with trial protocols.
Inferred coverage considerations for PNS and restorative neurostimulation
Study populations and technology assessments suggest coverage considerations when ALL of the following apply:
Patient selection and prior therapy: Patient has chronic pain refractory to multiple conservative and nonsurgical treatments as documented in clinical records
Supported by study inclusion criteria for PNS and restorative neurostimulation trials.
Baseline measurements: Baseline pain and disability scores (eg, VAS/NRS, ODI) and opioid usage (MME) are documented
Trials reported baseline and follow-up VAS/ODI and opioid MME (Gilmore, Gilligan).
Treatment intent and device-specific protocol: Planned use matches studied protocols (eg, percutaneous PNS for 60 days; ReActiv8 implant activation and usage per device regimen)
Effectiveness and durability data tied to specific device regimens.
ReActiv8: candidate criteria, evidence summary, and safety
Coverage considerations derived from available evidence and trial inclusion criteria
ReActiv8 candidate selection: Patient has refractory mechanical chronic low back pain with impaired multifidus control, has failed >90 days of medical management including at least one attempt of physical therapy, and is not a surgical candidate>90 days
Based on inclusion criteria and HTA summaries from ReActiv8 trials.
Evidence strength and outcome expectations: Trial data show mixed between-group effects at early endpoints with observational follow-up reporting durable improvements in subsets; interpret expected benefit cautiously given attrition and study limitations
ECRI and Hayes identify limited and heterogeneous evidence.
Safety considerations: Serious adverse events have been reported (eg, pocket infections requiring removal); device explant and revision may occur and should be discussed with patients
Scrambler Therapy and PoNS: evidence-based coverage considerations
Scrambler Therapy evidence: Systematic reviews and small RCTs provide low-to-very-low quality evidence with inconsistent results for scrambler therapy across chronic pain conditions; guideline panels (ASCO, ESMO) do not recommend routine use for CIPN outside clinical trials.
Hayes, Jin et al., ASCO, ESMO guidelines.
PoNS (translingual stimulation): PoNS (TLNS) has De Novo FDA clearance for short-term adjunctive treatment of gait deficit due to mild-to-moderate MS in adults ≥22 when used with supervised therapeutic exercise; randomized trials in mmTBI and MS paired PoNS with PT and enrolled patients plateaued after PT—evidence is inconclusive and additional studies are needed.
ECRI assessment concluded evidence inconclusive; FDA De Novo indication specifies age ≥22 and adjunctive supervised PT.
Covered with conditions / Evidence summary
Evidence summary and implied coverage considerations
TLS/PoNS coverage considerations: PoNS is FDA De Novo–cleared for short-term adjunctive treatment of gait deficit due to mild-to-moderate multiple sclerosis in adults ≥22 years and was studied as paired with supervised therapeutic exercise in patients who had plateaued after prior PT; outside this indication evidence remains inconclusive and use should align with the FDA-cleared patient and program requirements.
Device labeling requires prescription and adjunct to supervised therapeutic exercise.
Indication-concordant use
Covered when ALL of the following are met (per FDA-cleared indication):
PoNS indication criteria: (1) Diagnosis: gait deficit due to mild to moderate multiple sclerosis; (2) Age: patient is 22 years of age or older; (3) Treatment context: used as an adjunct to a supervised therapeutic exercise program; (4) Authorization: prescribed by a licensed provider (prescription only).
Derived from FDA De Novo clearance description and device labeling.
Hayes' Evidence Analysis Research Brief concluded there is insufficient published peer-reviewed literature to support home‑based functional electrical stimulation (FES) for rehabilitation after spinal cord injury (SCI). The review (six abstracts including one RCT and a single‑arm study) found no clinical position statements or guidelines addressing home‑based FES for SCI and characterized the level of support as no/unclear for this indication.
Across indications the evidence base for FES/NMES and related electrotherapies is heterogeneous and often limited by small sample sizes, variable devices/protocols, short follow‑up, and risk of bias. Health technology assessments and systematic reviews report low‑quality or inconsistent findings for functional recovery and quality‑of‑life outcomes in stroke, MS, ICU populations and other conditions, and call for larger, standardized RCTs with longer follow‑up to clarify clinical benefit.
Certain modalities and indications are explicitly limited by guideline or assessment conclusions. NICE recommends limiting transcutaneous NMES for oropharyngeal dysphagia to special governance or research arrangements; NICE also recommends that IFT/IFC, TENS and PENS should not be offered for low back pain with or without sciatica and that IFT should not be offered for knee osteoarthritis. Technology assessments (Hayes, ECRI) and guideline panels have identified insufficient or very‑low quality evidence to support routine use of many implantable PNS systems and scrambler therapy; PoNS/TLS evidence is inconclusive except for the narrow FDA De Novo indication. The policy therefore notes that therapies and device uses lacking adequate high‑quality evidence may be considered unproven/investigational or not medically necessary unless otherwise specified in the coverage criteria.
Procedural or diagnostic exclusions are not enumerated broadly in the excerpt; rather, guidance and HTAs identify situations where routine coverage is not supported. For example, NICE advises that NMES for dysphagia should only be provided under special arrangements (governance/consent/audit or research), and NICE further recommends against offering IFT/IFC and PENS/TENS for low back pain with or without sciatica due to insufficient evidence. Hayes and ECRI assessments similarly flag specific implantable PNS applications as unsupported by robust peer‑reviewed evidence, implying potential restriction or denial for those device‑indication combinations in routine practice.
NICE's guidance on transcutaneous NMES for oropharyngeal dysphagia emphasizes limited evidence and recommends that use should occur only with special arrangements for clinical governance, consent, audit, or within research. The guideline notes potential benefits but calls for better‑designed studies and careful documentation of patient selection when NMES is used for dysphagia.
NICE and recent systematic reviews conclude that interferential therapy/interferential current (IFT/IFC) evidence is inconsistent and generally does not support routine clinical use for many musculoskeletal indications. NICE specifically recommends that IFT should not be offered for knee osteoarthritis, chronic primary pain, or low back pain with or without sciatica because trials are small, heterogeneous, and provide uncertain clinical benefit.
NICE updated guidance (2016, updated 2020–2022) explicitly states that TENS, PENS and IFT should not be offered for low back pain with or without sciatica owing to paucity of high‑quality evidence and lack of sustained benefit beyond the short term. This recommendation informs the policy stance that these modalities are not supported as routine therapy for LBP/sciatica.
NICE's assessment and HTAs conclude that evidence for percutaneous electrical nerve stimulation (PENS) in chronic low back pain is very low quality. While some short‑term, statistically significant differences versus baseline have been reported, these are typically not clinically durable, and NICE recommends against offering PENS for LBP/sciatica in routine practice—PENS is therefore not recommended as first‑line therapy for these indications.
Health technology assessments (Hayes, ECRI) find the body of evidence for many implantable peripheral nerve stimulation (PNS) systems to be limited, heterogeneous, and of low or very‑low quality. While some small trials and case series report pain reductions and functional gains, reviewers conclude that larger, blinded RCTs with longer follow‑up are needed before definitive conclusions about routine use can be drawn; this supports a cautious coverage approach and likely requirement for device‑specific authorization and documentation.
Systematic reviews, HTAs, and oncology guideline panels conclude scrambler therapy evidence is low to very low quality and inconsistent. ASCO and ESMO/EONS/EANO advise against routine use of scrambler therapy for chemotherapy‑induced peripheral neuropathy outside clinical trials, and Hayes finds insufficient evidence to draw firm conclusions on its efficacy and long‑term safety.
Translingual stimulation (TLS)/PoNS has limited and inconclusive evidence: ECRI's assessment and systematic reviews report too few high‑quality data to establish long‑term safety or efficacy for gait and balance disorders. PoNS received FDA De Novo clearance only for short‑term adjunctive use in adults aged ≥22 with mild‑to‑moderate MS-related gait deficit, and broader indications remain unsupported by robust independent trials.
The policy clarifies scope: outside the explicitly listed, evidence‑concordant indications (e.g., FES for SCI meeting device and functional criteria; NMES for disuse atrophy/post‑TKA/post‑stroke upper‑extremity use when part of comprehensive rehab), the use of FES and NMES modalities is considered unproven and not medically necessary due to insufficient or low‑quality evidence.
For home‑based FES in spinal cord injury rehabilitation, Hayes' brief found insufficient peer‑reviewed evidence and no clinical guidelines endorsing home‑based use, supporting the conclusion that current evidence is inadequate to establish benefit for home‑based FES after SCI.
A recent multicenter randomized trial (Matsumoto et al. 2023) in convalescent post‑stroke patients with foot drop found no significant improvement in barefoot 6‑minute walk distance with FES versus control, and HTA summaries note overall low‑quality evidence and inconsistent functional benefits—highlighting uncertainty of FES efficacy in some stroke populations.
In ICU and critically ill populations, RCTs have not consistently shown that adding NMES/FES to standard early rehabilitation improves muscle strength at discharge or long‑term functional outcomes. Large trials (for example, Waldauf et al. and Fossat et al.) reported no sustained benefit on key disability endpoints, indicating insufficient evidence to support routine adjunctive use in heterogeneous ICU cohorts.
For COPD outpatient populations, systematic reviews and meta‑analyses report inconsistent or low‑quality evidence. While some trials show improvements in quadriceps force or submaximal exercise tolerance, pooled analyses found no reliable benefit for peak VO2 or health‑related quality of life and concluded that NMES should not replace pulmonary rehabilitation based on current data.
The evidence does not support NMES as an alternative to comprehensive pulmonary rehabilitation for COPD. Reviews conclude that NMES may increase certain muscle performance measures when used alone, but quality of evidence is low to very low and it does not demonstrate equivalence or superiority to standard rehabilitation programs.
Interferential therapy/interferential current (IFT/IFC) lacks consistent high‑quality evidence for many musculoskeletal indications. Meta‑analyses and guideline panels (including NICE) found at best short‑term pain reductions in some trials but overall heterogeneity and limited clinical durability, supporting a conservative reimbursement stance for routine IFT/IFC use.
For chronic low back pain, the totality of evidence for PENS and related percutaneous modalities is of very low quality with short‑term or inconsistent effects. NICE updates explicitly advise against offering these modalities for routine LBP/sciatica care, and systematic reviews conclude insufficient long‑term benefit—thereby informing the policy's non‑routine coverage position for LBP indications.
Across many peripheral nerve stimulation (PNS) indications, available studies are small, heterogeneous, or otherwise at high risk of bias; systematic reviews and HTAs therefore judge the evidence insufficient to make broad recommendations. This general insufficiency supports selective, indication‑specific coverage and the expectation of device‑specific authorization and thorough documentation when PNS is considered.
Given the limited quantity and quality of evidence for many PNS systems and indications, reviewers caution payers and clinicians to interpret reported benefits carefully; the policy notes the low certainty of effect estimates and recommends conservative coverage decisions where evidence is minimal or of very low quality.
Treatments lacking adequate, high‑quality evidence—such as scrambler therapy for many chronic pain conditions and PoNS/TLS for gait/balance outside the specific FDA‑cleared indication—are considered investigational or not medically necessary for routine coverage until more definitive data are available.
Translingual stimulation (TLS) carries investigational risk because robust, independent long‑term studies are lacking. Although the PoNS device has FDA De Novo clearance for a limited, short‑term adjunctive use in adults ≥22 with mild‑to‑moderate MS, evidence outside that indication is inconclusive and does not support routine coverage.
TLS investigational considerations include the lack of robust long‑term safety and efficacy data across neurologic indications; existing RCTs were concentrated at a single research center and independent confirmatory trials are needed before broader clinical adoption can be supported.
The policy revision removed prior language that explicitly labeled certain transcutaneous joint stimulation devices as not medically necessary and revised NMES/FES clinical criteria. The updated coverage rationale adds specific, evidence‑concordant criteria for FES and NMES indications while removing obsolete InterQual operational references.
Applicable Codes and Billing
Device product codes and regulatory identifiers referencedmixed
TENS / MENS / Scrambler device product code (FDA reference)
Product Code NHI
PENS device product code (FDA reference)
Product Code PZR
PSFS / PNFS device product code (FDA reference)
Product Code QLK
ReActiv8 restorative neurostimulation system (PMA) product code
PoNS De Novo
PoNS device granted De Novo approval (March 25, 2021) for TLS
Applicable HCPCS codes (revisions noted)HCPCS
E0762
HCPCS code E0762 (removed from applicable codes section)
E0721
HCPCS code E0721 (description revised)
Applicable HCPCS codes (revisions noted)HCPCS
E0762
HCPCS code E0762 (removed from applicable codes section)
E0721
HCPCS code E0721 (description revised)
Post-recovery duration before FES
Minimum post-recovery intervalAt least 6 months after recovery from spinal cord injury or restorative surgery
Functional prerequisitesIndependent standing tolerance for >= 3 minutes before FES consideration
Neurologic status requirementDemonstration of intact lower motor units (L1 and below) — muscle and peripheral nerves
Orthopedic exclusionAbsence of hip or knee degenerative disease
Prior Authorization, Documentation, and Provider Requirements
Prior Authorization
Prior Authorization Required for Implanted Neuromodulation Devices
Implantable neuromodulation devices require device-specific prior authorization. Device model, implantation procedure, indication, prior conservative therapy, and planned therapy duration should be provided to facilitate review.
Provide device make/model and FDA clearance status (e.g., ReActiv8, StimRouter, SPRINT, Nalu, PoNS).
Include operative/implantation notes and intended stimulation protocol (hours/day, total planned duration).
Document prior conservative care (physical therapy, medications, orthoses) and rationale for implant.
Attach clinician specialty and device-specific training or credentialing when applicable.
Billing Rule
Billing/Coding Update — HCPCS E0762 Removed
Prior Conservative Therapy and Stepwise Care
Conservative treatment requirements (placeholder)
Conservative treatment requirements (placeholder)
Conservative therapy first consideration: Preferential use of exercise and multidisciplinary rehabilitation is recommended prior to considering electrical stimulation modalities; document the nature and duration of prior conservative care.
Guidelines and trials commonly used prior PT and conservative measures as prerequisites.
Trial of AFO and supervised physical therapy may be expected prior to FES for foot drop or gait impairment.
Trial of AFO and supervised physical therapy may be expected prior to FES for foot drop or gait impairment.
AFO and PT trial before FES: Trial of an appropriately fitted ankle–foot orthosis (AFO) and supervised physical therapy with documented participation and plateau may be expected prior to consideration of FES for foot drop or gait impairment.
MS and CP studies commonly compared FES versus AFO and required PT in study protocols.
Definitions of Devices and Modalities
Percutaneous Electrical Nerve Field Stimulation (PENFS)
DefinitionPercutaneous electrical nerve field stimulation (PENFS) uses low-frequency electrical current to stimulate the skin and underlying tissues over a general area (often auricular) to modulate central pain pathways via peripheral cranial neurovascular bundles
Typical applicationUsed in pediatric functional GI disorders and chronic pain studies with short treatment courses (e.g., 4 weeks in some pediatric DGBI/IBS trials)
Evidence qualityOverall evidence is limited, with small studies and short follow-up; further robust studies recommended
Percutaneous Peripheral Nerve Stimulation (PNS)
DefinitionPercutaneous peripheral nerve stimulation (PNS) places electrode(s) near a peripheral nerve to deliver impulses that disrupt pain signal transmission
Therapy Frequency and Duration as Studied
Implanted PNS and restorative neurostimulation devices (reference)
Regulatory sourcesFDA product codes and De Novo identifier for PoNS cited as reference points for device regulation and labeling
Coding implicationDevice-specific product codes can guide regulatory classification and evidence assessment for coverage determinations
FES therapy sessions (typical study protocols)
Typical FES session frequencyStudy protocols describe FES delivered up to daily or 5 times/week regimens (examples: 40 min/day 5 days/week for 8 weeks; 30 min, 3x/week for 8 weeks)
Cardiac (CHF) program
Imaging and Diagnostic Testing Expectations
Note
PNS, PSFS implantation — imaging implied
Implantation of PNS or PSFS involves placing leads near peripheral nerves or within subcutaneous tissue; while not explicitly stated, the descriptions imply imaging guidance (e.g., fluoroscopy or ultrasound) is typically used during implantation.
Imaging guidance (fluoroscopy/ultrasound) is commonly implied for accurate lead placement.
Note
Documentation Required
NMES — no imaging requirement
NMES study reports do not mandate imaging guidance for therapy delivery; NMES is typically transcutaneous and does not require imaging.
Not Medically Necessary / Investigational
Summary placeholder: The policy lists specific indications that are covered when criteria are met and identifies multiple modalities and indications that lack sufficient high‑quality evidence for routine coverage; see the coverage criteria and not‑medically‑necessary sections for details.
HTA‑level caution: Hayes and ECRI assessments conclude that evidence for many implantable PNS systems is limited and of low quality, and they recommend further large, independent RCTs before routine adoption; this supports careful, case‑by‑case coverage review for implantable PNS.
Placeholder: Specific procedural exclusions and not‑covered lists are determined by the coverage criteria and evidence summaries; refer to the policy's coverage logic for explicit rules.
Placeholder: Where evidence is insufficient, requests may be evaluated as investigational and subject to denial unless compelling device‑specific data and trial‑matching documentation are provided.
Placeholder: For novel or device‑specific implantable neuromodulation systems lacking peer‑reviewed evidence, prior authorization and medical review are likely required.
Placeholder: Routine coverage is generally reserved for indications where the policy lists explicit, evidence‑aligned criteria; other uses remain unproven.
Placeholder: Documentation of prior conservative therapies, baseline measures, and device‑specific protocols supports coverage decisions and may be requested.
Placeholder: For devices cleared or approved for narrow indications (e.g., PoNS), coverage is expected only when use aligns with regulatory labeling and trial‑based protocols.
Background and Scope
This policy addresses multiple electrical stimulation modalities used for pain modulation and rehabilitation. Definitions include PENFS (percutaneous electrical nerve field stimulation), PNS (percutaneous peripheral nerve stimulation), PSFS (peripheral subcutaneous field stimulation), PES/PEMF (pulsed electrical/magnetic stimulation), restorative neurostimulation (e.g., ReActiv8 targeting multifidus), scrambler therapy, TENS, TLS/PoNS (translingual stimulation), and FES/NMES. Modalities differ by target (muscle contraction vs. sensory modulation), invasiveness (surface, percutaneous, implanted), and intended clinical use (assistive device vs. rehabilitative therapy).
Policy Revision History and Changes
04/01/2026policy_revisionLatest
Revised Coverage Rationale: removed language that Transcutaneous electrical joint stimulation is not considered medically necessary and removed prior statements that NMES and FES were medically necessary in certain circumstances; updated medical necessity clinical coverage criteria and removed references to InterQual modules for TEJSD and NMES.
policy_revision_detail_added
Added detailed criteria specifying when Functional Electrical Stimulation (FES) is proven and medically necessary for ambulation rehabilitation after spinal cord injury (intact lower motor units, muscle/joint stability, brisk muscle contraction, sensory perception, motivation/cognition, independent transfers and standing tolerance ≥3 minutes, hand function, ≥6 months post-recovery, absence of hip/knee degenerative disease and no osteoporotic long-bone fractures).
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation
Low back pain (IFT): IFT/IFC may reduce pain intensity and disability immediately post-treatment versus placebo in NSCLBP, but benefits are not sustained at intermediate follow-up and guideline panels (NICE) do not support routine use in many settings.
Rampazo et al., Hussein et al., NICE.
Knee osteoarthritis and post-TKA (IFC/IFT): Systematic reviews report short-term pain and some function improvements with IFC/IFT in knee OA, with network meta-analysis identifying IFT as relatively promising among electrotherapies; results are heterogeneous and recommendations vary.
Chen et al., Zeng et al.
Guideline caution for LBP/sciatica: NICE recommends not offering TENS, PENS, or IFT for low back pain with or without sciatica due to insufficient evidence and lack of sustained benefit beyond four months.
NICE 2016 updated 2022
Goree 2024, Gilmore 2023.
Evidence sufficiency: High-quality randomized data or guideline endorsement for the specific device/indication is available
HTAs note low/very-low quality evidence for many PNS devices; lack of high-quality evidence may affect coverage.
Gilligan 2021 reported ~4% SAE rate including pocket infections.
HCPCS coding changes affecting billing have been made: HCPCS code E0762 was removed and HCPCS code E0721 description was revised. Providers must update claims to the current code set and ensure prior authorization requests reference valid, supported HCPCS/CPT codes.
HCPCS code E0762 — REMOVED (do not use on claims or prior authorization requests).
HCPCS code E0721 — revised description; verify and use the updated descriptor when billing.
Ensure documentation submitted for authorization references current codes and device identifiers.
Support for conservative-treatment evidence snippets
MS FES conservative context: FES studies in MS frequently compared outcomes to AFOs and reported similar walking-speed benefits; prior conservative therapy and documentation of functional goals are typical in trial protocols.
Hayes HTA and Miller et al. reviews describe comparative study designs.
NMES as adjunct to therapy: NMES is often studied as an adjunct to strengthening, gait training, or swallowing therapy rather than as a standalone replacement for comprehensive rehabilitation.
CP and stroke reviews report NMES combined with therapeutic exercise.
Pulmonary rehab precedence: Systematic reviews in COPD indicate NMES should not replace pulmonary rehabilitation; standard pulmonary rehab remains first-line and should be documented prior to considering NMES as adjunctive therapy.
Cochrane and Wu et al. reviews support pulmonary rehab as standard.
Preferential use of exercise/multidisciplinary rehabilitation before considering ES modalities.
Preferential use of exercise/multidisciplinary rehabilitation before considering ES modalities.
Noninvasive-first approach: Clinical guidelines recommend selecting nonpharmacologic treatments such as supervised exercise and multidisciplinary rehabilitation as initial therapy for conditions like chronic low back pain, with electrical stimulation modalities considered adjunctive.
ACP and NICE guideline language support this approach.
Trial of conservative therapy recommended before considering PENS (implied by low-quality evidence and not-first-line recommendations).
Trial of conservative therapy recommended before considering PENS (implied by low-quality evidence and not-first-line recommendations).
PENS conservative trial: Documented trial of conservative therapies (eg, exercise, medication, PT) is recommended before considering PENS, consistent with guideline caution that PENS is not first-line for many musculoskeletal conditions.
NICE and AAOS guidance note limited evidence and training requirements for PENS.
Document prior failure of appropriate conservative and pharmacologic therapies before considering PENFS/PNS.
Document prior failure of appropriate conservative and pharmacologic therapies before considering PENFS/PNS.
Document prior failure: For PENFS and PNS indications studied (eg, pediatric DGBI for PENFS; CLBP or postoperative pain for PNS), document prior failure of appropriate conservative and pharmacologic therapies consistent with study inclusion criteria before considering device therapy.
PENFS pediatric trials and PNS studies typically enrolled patients refractory to multiple medication trials or conservative care.
Documented failure of multiple conservative treatments prior to consideration of neuromodulation is expected per study populations.
Documented failure of multiple conservative treatments prior to consideration of neuromodulation is expected per study populations.
Refractory patient requirement: Study populations for PNS and restorative neurostimulation generally consisted of patients refractory to multiple nonsurgical/conservative treatments; documentation of these failures is expected when requesting device therapy.
Gilmore and ReActiv8 trials enrolled refractory patients.
Documented failure of conservative therapy including physical therapy and medications prior to consideration of implantable restorative neurostimulation
Documented failure of conservative therapy including physical therapy and medications prior to consideration of implantable restorative neurostimulation
>90 days conservative care: Documented failure of conservative therapy including physical therapy and medications for greater than 90 days is expected prior to consideration of implantable restorative neurostimulation (eg, ReActiv8 trial entry criteria).>90 days
ReActiv8 RCT required >90 days of medical management including at least one PT attempt.
Prior supervised physical therapy with documented plateau is expected before considering TLS in trials.
Prior supervised physical therapy with documented plateau is expected before considering TLS in trials.
Prior supervised PT and plateau: Trials of translingual stimulation (PoNS/TLNS) required prior supervised physical therapy with documented plateau in recovery and the ability to ambulate (eg, walk independently for at least 20 minutes); similar documentation may be expected for coverage review when considering TLS.
Ptito and Hou TLNS studies enrolled participants who had plateaued after PT and could ambulate.
Device must be used as an adjunct to a supervised therapeutic exercise program (per FDA indication).
Device must be used as an adjunct to a supervised therapeutic exercise program (per FDA indication).
Adjunctive use requirement: For PoNS (TLS), device use must be adjunctive to a supervised therapeutic exercise program and prescribed by a licensed provider in adults aged 22 years and older, consistent with FDA De Novo labeling.
FDA De Novo states adjunct to supervised therapeutic exercise and prescription-only use.
Use within comprehensive rehabilitation program
Use within comprehensive rehabilitation program
Program-integrated use: NMES and FES applications described in trials were delivered as components of comprehensive rehabilitation programs (eg, combined with PT, gait training, or exercise programs); consider coverage only when use is integrated within a documented rehabilitation plan.
Post-TKA and post-stroke NMES studies and many FES protocols were adjunctive to rehab programs.
Forms studied
Includes percutaneous leads (externally powered or implantable) targeting nerves such as femoral, sciatic, saphenous, and medial branch
Evidence summaryEvidence is limited and heterogeneous; some RCTs (e.g., post-TKA) and case series report meaningful pain reduction, but larger RCTs are needed
Peripheral Subcutaneous Field Stimulation (PSFS)
DefinitionPeripheral subcutaneous field stimulation (PSFS/PNFS) implants electrode arrays within subcutaneous tissue of the painful area (not on named nerves) to stimulate cutaneous nerve endings
Indication contextUsed when painful field is not well defined or does not fit within territory of a single peripheral nerve
DistinctionDifferent from PNS and SCS because leads are placed in subcutaneous tissues rather than on identified neural structures
Pulsed Electrical Stimulation (PES)
DefinitionPulsed electrical stimulation (PES) delivers pulsed electric or electromagnetic fields hypothesized to affect cellular processes (bone/cartilage repair, inflammation) via electrostatic/electrodynamic effects
Clinical useStudied for musculoskeletal conditions including osteoarthritis and postoperative recovery; protocols vary widely
Evidence summaryCurrent evidence is insufficient to support broad clinical use; RCTs show mixed results and further trials recommended
Restorative Neurostimulation
DefinitionRestorative neurostimulation is an implantable therapy that stimulates the lumbar multifidus via leads placed near the medial branch of the dorsal ramus to rehabilitate neuromuscular control in mechanical chronic low back pain (example: ReActiv8)
Therapy regimenImplanted device delivers programmed stimulation sessions (twice daily in ReActiv8 studies) with documented follow-up up to multi-year timepoints
Candidate profileStudies enrolled patients with refractory mechanical CLBP, multifidus dysfunction, and >90 days of failed conservative management
Scrambler Therapy
DefinitionScrambler Therapy (ST) is a noninvasive transdermal treatment applying electrodes to dermatome-corresponding skin to provide non-pain information via variable nonlinear waveforms for symptomatic chronic pain relief
Typical protocolCommonly delivered daily over successive weekdays (e.g., 10 sessions over 2 weeks in many reports)
Evidence stancePublished evidence is limited and inconsistent; systematic reviews conclude insufficient evidence for definitive efficacy
DefinitionTranscutaneous electrical nerve stimulation (TENS) uses surface electrodes to deliver electrical current to reduce pain perception by inhibiting afferent pain impulses and/or stimulating endorphin release
Clinical roleStudied across musculoskeletal and neuropathic pain conditions; evidence varies by indication with limited long-term data
Guideline noteNICE recommends against routine use of TENS for low back pain with or without sciatica due to insufficient evidence
Translingual Stimulation (TLS)
DefinitionTranslingual stimulation (TLS) delivers neuromuscular electrical stimulation to the tongue (e.g., PoNS) to stimulate trigeminal and facial cranial nerve input and augment neuroplasticity with therapy
Regulatory notePoNS (Portable Neuromodulation Stimulator) received FDA De Novo clearance (March 25, 2021) for short-term adjunctive treatment of gait deficit due to mild-to-moderate MS in adults >=22 years by prescription only
Evidence summaryECRI and other assessments find evidence inconclusive and recommend additional independent trials; long-term safety/efficacy data are limited
Functional Electrical Stimulation (FES)
DefinitionFunctional electrical stimulation (FES) applies electrical stimulation to produce functional movements (e.g., correct foot drop) to improve ambulation and gait in neurologic conditions
Use contextsUsed in stroke, cerebral palsy, incomplete spinal cord injury, FES-assisted cycling and gait training protocols
Evidence summaryRCTs and reviews show mixed results: some improvements in ankle dorsiflexion, balance and gait kinematics; overall evidence quality and generalizability vary
Assistive versus rehabilitative FES
Assistive FESApplied during ambulation to substitute for impaired function (e.g., device used to correct foot drop during walking)
Rehabilitative FESUsed within structured therapy to promote recovery of function (e.g., FES-assisted cycling, gait retraining)
Policy distinctionHTAs and evidence syntheses differentiate evidence quality between assistive (device-as-augmentation) and rehabilitative (therapy-driven) uses
FES definition
Core definitionFES produces functional movements (eg, correcting foot drop) by applying electrical stimulation to motor nerves/muscles as part of ambulation rehabilitation
Intended benefitImprove gait, walking speed/distance, balance, and functional mobility in neurologic gait disorders
Evidence caveatMost studies are small with short follow-up; benefits vary by condition and whether used with supervised exercise/therapy
NMES definition
DefinitionNeuromuscular electrical stimulation (NMES) applies transcutaneous electrical stimulation to produce muscle contractions for rehabilitation, prevention of atrophy, or improved function
ApplicationsUsed for disuse atrophy, ICU-acquired weakness, swallowing/dysphagia therapy, post-op quadriceps strengthening and gait training
Evidence summaryEvidence supports NMES for disuse atrophy when nerve supply intact; other indications have mixed or low-quality evidence requiring further trials
NMES (alternate chunks)
Alternate descriptionNMES (neuromuscular electrical stimulation) delivered transcutaneously elicits muscle contractions and is studied to augment strengthening, gait training, and reduce spasticity
Protocol variabilityDosing, frequency, and duration vary widely across studies (minutes to hours per day; weeks duration)
CCFES descriptionContralaterally controlled functional electrical stimulation (CCFES) uses the nonparetic limb to control stimulation parameters applied to the paretic limb to assist movement during rehabilitation
Clinical contextStudied in subacute stroke for upper limb motor recovery with short courses (eg, 20 minutes/day, 5 days/week for 3 weeks in some trials)
Comparative findingsSome trials show improved motor outcomes versus baseline but not consistently superior to NMES; further validation needed
NMES (additional definition)
NMES additional noteNMES is applied transcutaneously to muscles to elicit contractions; studied across ICU, COPD, post-op, and neurorehabilitation settings
Evidence heterogeneityStudy results and quality vary; some systematic reviews report benefits for muscle force/endurance but low/very low overall evidence
Guidance implicationNICE recommends governance/research arrangements for some NMES uses (eg, dysphagia) due to insufficient high-quality evidence
IFT / IFC
DefinitionInterferential therapy (IFT/IFC) uses medium-frequency electrical currents intended for pain modulation and rehabilitation
Knee OA evidenceNetwork and systematic reviews (eg, Zeng 2015; Chen 2022a) identify IFC/IFT as among the more promising electrotherapies for short-term pain relief in knee OA, though trial heterogeneity exists
Guideline cautionNICE advises against offering IFT for several indications (eg, knee OA, chronic primary pain, low back pain) due to inconsistent evidence
IFT/IFC (additional)
Additional noteMeta-analyses show IFT may reduce pain immediately post-treatment for NSCLBP but not at intermediate-term follow-up; evidence quality and protocol variability limit conclusions
Study countsSystematic reviews include dozens of RCTs (eg, Hussein et al. reviewed 35 RCTs; Rampazo 2023 included 13 RCTs for NSCLBP)
Clinical implicationIFT/IFC may provide short-term benefit but is not consistently supported for sustained clinical improvement across conditions
MENS/MET/FSM
DefinitionMicrocurrent electrical nerve stimulation (MENS/MET/FSM) delivers very low-amplitude currents (microampere range) investigated for pain and tissue healing
Evidence baseSmall RCTs and meta-analyses show modest short-term pain reductions in select conditions (eg, masticatory myofascial pain); larger trials are lacking
Clinical cautionConclusions limited by small samples, heterogeneity, and short follow-up; further robust RCTs needed
TEAS
DefinitionTranscutaneous electrical acupoint stimulation (TEAS) applies stimulation through the skin at acupuncture points, used perioperatively and postoperatively
Perioperative evidenceSystematic reviews (eg, Tan et al.) report reduced short-term postoperative pain and opioid consumption, but effects are often small and short-lived
Protocol variabilityStudies vary in frequencies, acupoints, and session timing; heterogeneity limits generalizability
MENS
MENS specific noteSmall RCTs in elderly and OA populations reported short-term improvements in muscle function or pain, but results are inconsistent across trials
Study limitationsTrials often small (eg, n≈38-52), short duration, and lack long-term follow-up
RecommendationFurther long-term, larger RCTs needed to establish clinical utility
PENS
DefinitionPercutaneous electrical nerve stimulation (PENS) is needle-based electrical stimulation in or near peripheral nerves for musculoskeletal and neuropathic pain
Outcome profileSystematic reviews report mild-to-moderate immediate pain reduction, but long-term benefit is unclear and evidence is limited
Practice implicationPENS often studied as adjunct to other therapies; not recommended as first-line for many musculoskeletal indications per guideline cautions
PENS / PENFS
PENS/PENFS relationshipPENS (percutaneous) and PENFS (field/auricular) are minimally invasive neurostimulation techniques using percutaneous or auricular leads to modulate pain signaling
Indications studiedUsed for musculoskeletal pain, neuropathic pain, and pediatric functional GI disorders; protocols and evidence vary by indication
Guideline pointsAAOS notes PENS requires trained practitioners; NICE recommends against PENS/TENS/IFT for low back pain due to insufficient evidence
PNS
PNS summarizedPercutaneous PNS involves placement of percutaneous leads targeting peripheral nerves (eg, femoral, sciatic, medial branch) to reduce postoperative or chronic localized pain
Treatment coursesProtocols include 60-day implanted percutaneous PNS courses with daily use (eg, Gilmore 2023 medial branch protocol)
EvidenceSome RCTs show ≥50% responder rates versus placebo in post-TKA and case series show durable improvements in CLBP, but overall evidence quality varies
Restorative neurostimulation (ReActiv8)
ReActiv8 summaryReActiv8 is an implantable restorative neurostimulation system targeting multifidus to improve function and reduce chronic low back pain
Therapy dosingImplant delivers programmed stimulation sessions twice daily in trials; randomized trial used twice-daily stimulation for 120 days as primary period
Evidence and safetyRCT and long-term follow-up report clinically substantial improvements in many participants but attrition and SAE (eg, 4% SAE rate, infections) noted
Percutaneous PNS
Percutaneous PNS (implant) notePercutaneous PNS protocols in trials often used leads left in place for several weeks (eg, 60 days) with daily usage targets (eg, 6–12 hours/day)
TargetsFemoral, sciatic, saphenous, and medial branch targets reported for postoperative and chronic pain indications
Evidence caveatPublished studies include RCTs and prospective series but overall evidence remains heterogeneous; larger multicenter RCTs encouraged
PEMF/PES
PEMF/PES summaryPulsed electromagnetic field (PEMF) or pulsed electrical stimulation therapies apply electromagnetic or electrical fields to modulate pain, inflammation, or tissue healing
Orthopedic trial examplePost-UKA PEMF trial instructed 4 hours/day for 60 days in D'Ambrosi 2022 study
EvidenceSystematic reviews and RCTs show mixed results; overall evidence insufficient for broad support and further trials needed
ReActiv8 (quick ref)
ReActiv8 quick refImplantable restorative neurostimulation (ReActiv8) targets multifidus with twice-daily sessions; RCT and long-term follow-up report sustained improvements in many patients
Candidate selectionStudies enrolled patients with refractory mechanical CLBP and documented multifidus dysfunction after >90 days of medical management
Safety considerationsDevice-related serious adverse events (eg, pocket infections) have been reported; evaluation of risks/benefits required
Scrambler Therapy definition
Scrambler Therapy definitionNoninvasive transdermal delivery of variable nonlinear electrical waveforms to dermatomal skin areas to convey non-pain information to the nervous system for symptomatic relief
Typical deliverySession-based treatments often delivered daily over consecutive weekdays (eg, 10 sessions over 2 weeks)
Evidence stanceSystematic reviews conclude insufficient high-quality evidence to support routine use; guidelines do not recommend routine use for some indications (eg, CIPN)
Translingual stimulation / PoNS
TLS / PoNS definitionTranslingual stimulation (PoNS) is a nonimplantable neuromuscular tongue stimulator delivering stimulation to the dorsal tongue surface combined with supervised therapeutic exercise to augment neuroplasticity
FDA-cleared indicationPoNS De Novo: short-term adjunctive treatment of gait deficit due to mild-to-moderate MS in adults >=22 years, by prescription only
Evidence summaryRCTs and assessments report inconclusive evidence overall; independent studies recommended to confirm benefits and durability
Portable Neuromodulation Stimulator (PoNS)
PoNS devicePortable Neuromodulation Stimulator (PoNS) is a nonimplantable device with a mouthpiece that delivers NMES to the dorsal surface of the tongue
Regulatory statusGranted FDA De Novo approval March 25, 2021 for short-term adjunctive treatment of gait deficit due to mild-to-moderate MS in adults >=22 years
Clinical contextTrials paired PoNS with supervised therapeutic exercise and enrolled patients who had plateaued after PT; evidence inconclusive per ECRI
TLS/TLNS
TLS / TLNS terminologyTranslingual stimulation devices (TLS/TLNS) are neuromuscular tongue stimulators intended to treat motor deficits and augment rehabilitation
Indication limitsPoNS indicated for adults 22+ with mild-to-moderate MS gait deficit as adjunct to supervised therapeutic exercise; use outside this indication lacks robust evidence
Research noteEvidence includes a small number of RCTs from developer-linked centers; independent confirmatory studies recommended
Translingual Stimulation Devices
Device classTranslingual stimulation devices are classified as neuromuscular tongue stimulators; PoNS received De Novo FDA clearance
Usage requirementPoNS use requires a prescription and is to be used adjunctively with supervised therapeutic exercise per FDA description
Evidence cautionECRI and other assessments found evidence inconclusive; long-term efficacy and generalizability remain uncertain
PoNS (regulatory summary)
PoNS regulatory summaryPortable Neuromodulation Stimulator (PoNS) received FDA De Novo approval March 25, 2021 for short-term adjunctive treatment of gait deficit due to mild-to-moderate MS in patients aged 22+
Prescription onlyDevice indicated by prescription and intended to be used as adjunct to supervised therapeutic exercise program
Evidence considerationsRCTs show some improvements when combined with therapy but independent assessments find evidence inconclusive and recommend further studies
FES (medical necessity phrasing)
FES medical necessity phrasingFES is proven and medically necessary as part of comprehensive ambulation rehabilitation for lower limb paralysis due to SCI when specific neurologic and functional criteria are met
ScopeApplies to assistive or rehabilitative FES for foot drop and gait disorders in neurologic populations when criteria satisfied
Evidence caveatRCTs and reviews show mixed results across indications; policy limits coverage to criteria-matching scenarios
NMES (medical necessity phrasing)
NMES medical necessity phrasingNMES is proven and medically necessary for disuse muscle atrophy (nerve intact), as part of comprehensive lower limb rehab post-TKA, and to improve upper extremity function after stroke when used within comprehensive rehab
Use limitationsNMES use outside these listed indications is considered unproven and not medically necessary
Evidence noteEvidence supports certain post-op and disuse atrophy contexts; other indications have variable evidence quality
Kadoglou et al. studied a six-week FES training program
Pediatric/CP regimensFES cycling and training studies in CP used multi-week programs with repeated sessions (eg, 30 min sessions 3x/week for 8 weeks)
FES training for CHF (Kadoglou et al.)
CHF FES programSix-week FES training program as studied in Kadoglou et al. (randomized placebo-controlled trial)
Outcomes monitoredFollow-up included hospitalization and mortality outcomes with median follow-up ~383 days in Kadoglou trial
ImplicationShort-term FES programs may reduce HF-related hospitalizations but require further study for long-term benefit
IFT/IFC frequency notes
IFT/IFC frequency notesIFT/IFC protocols vary across RCTs; meta-analyses report immediate post-treatment pain and disability reductions but not consistent intermediate-term benefits
Trial heterogeneityTreatment parameters and session counts differ substantially across studies (limits pooled conclusions)
Clinical implicationIFT may provide short-term symptom relief but evidence for sustained benefit is inconsistent
PENS/TEAS frequency notes
PENS/TEAS frequency notesPENS and TEAS studies use variable dosing from single sessions up to multi-week regimens; perioperative TEAS trials often measure effects within 24 hours to 72 hours post-op
Typical TEAS perioperative dosingTEAS trials include multiple sessions across the immediate postoperative period (effects primarily short-term)
PENS dosing variabilityPENS studies range from single sessions to multiple sessions over weeks; long-term effects generally not established
Percutaneous PNS medial branch therapyAs studied in medial branch PNS for CLBP, treatment courses involved 60-day implanted therapy with daily usage targets (eg, 6–12 hrs/day)
Outcome durabilityGilmore 2023 reported clinically meaningful improvements sustained through 14 months after a 60-day treatment course in many participants
Study limitationsProspective case series lack randomization and control; larger RCTs needed for confirmatory evidence
Auricular PENFS for pediatric DGBI/IBS (4 weeks)
Auricular PENFS pediatric dosingPediatric DGBI/IBS studies frequently used 4 weeks of PENFS therapy or four weekly treatments in trial protocols
Patient selectionStudies often enrolled adolescents who had failed multiple pharmacologic therapies prior to PENFS
Evidence limitationsMany trials are small and open-label; randomized sham-controlled data are limited
Percutaneous PNS as studied (60 days)
Percutaneous PNS as studiedImplanted percutaneous PNS protocols commonly used a 60-day treatment period with leads in place for ~8 weeks and follow-up extending to 12 months or longer in some studies
Daily usageStudies instructed daily use (eg, at least 6 hours/day, up to 12 hours/day during the 60-day treatment course)
Post-treatment follow-upFollow-up assessments reported outcomes at multiple timepoints up to 14 months in some cohorts
PEMF use post-UKA (4 hrs/day for 60 days)
PEMF post-UKA regimenD'Ambrosi 2022 trial used PEMF for 4 hours per day for 60 days post-unicompartmental knee arthroplasty
Outcomes measuredPain (VAS), function (OKS), SF-36 and objective swelling measures over follow-up to 36 months
Evidence noteSome RCTs report benefits in pain and swelling metrics; overall evidence still limited by heterogeneity and follow-up durations
ReActiv8 (frequency reference)
ReActiv8 frequency referenceReActiv8 implant delivers programmed stimulation sessions twice daily as per clinical trial protocols
Trial dosingTherapeutic or low-level sham stimulation delivered twice daily for initial trial periods (eg, 120 days in RCT)
Follow-upLong-term follow-up reported clinically substantial improvements in many participants at multi-year timepoints in observational cohorts
Translingual stimulation (PoNS) frequency notes
PoNS regimen notesClinical trials paired PoNS stimulation with supervised therapeutic exercise sessions; treatment schedules and monitored adherence logged by device in trials
Age restrictionFDA indication limits use to patients 22 years of age and older
Indication contextUsed as short-term adjunct to supervised therapeutic exercise for gait deficits due to mild-to-moderate MS
NMES is transcutaneous and studies did not require imaging for application.
Documentation Required
MENS studies sometimes included musculoskeletal ultrasound outcomes
Some MENS trials included musculoskeletal ultrasound outcomes (e.g., decreased effusion on ultrasound); include imaging results when present in trial-based documentation.
Musculoskeletal ultrasound was used to document effusion changes in a MENS knee trial.
Documentation Required
PENS for median nerve / carpal tunnel — imaging optional per protocol
Ultrasound-guided PENS was used in a randomized trial targeting the median nerve for carpal tunnel syndrome; imaging guidance may be optional or used per protocol for target localization.
Ultrasound guidance used for median nerve PENS in CTS trial.
Documentation Required
PNS lead placement for postoperative knee pain — imaging likely recommended
PNS lead placement targeting femoral and sciatic nerves for postoperative knee pain in trials involved percutaneous lead placement; while not explicitly stated, imaging guidance for accurate lead placement is likely recommended.
Lead placement to femoral/sciatic targets implies image-guided technique.
Note
Note
ReActiv8 implant — no imaging-specific requirements stated
No imaging-specific requirements for ReActiv8 implantation are stated in the cited sections of the document.
Note
TLS/TLNS research assessments — not required for coverage
Research assessments for TLS/TLNS included imaging (resting-state functional connectivity) in small investigational studies, but these imaging assessments are research tools and not required for coverage.
Imaging used in small TLNS research studies is not required for routine coverage.
Note
Translingual stimulation (PoNS) — no imaging requirement stated
PoNS/TLNS device descriptions and trials reference the device and supervised therapy but do not state imaging requirements for coverage or device use.
Documentation Required
Documentation to include results of pertinent diagnostic tests or procedures as needed to support medical necessity.
Documentation submitted for coverage should include results of pertinent diagnostic tests or procedures as needed to support medical necessity (e.g., imaging or diagnostic test results when relevant to the indication).
Include relevant diagnostic test results when they support the medical necessity of the requested service.
Placeholder: Treatments categorized as investigational are not covered in routine practice absent strong new evidence or trial context.
Placeholder: Requests for PNS or restorative implants should document prior conservative care, objective baseline disability, and rationale for implant selection to align with trial populations.
Placeholder: Coverage decisions for electrotherapy modalities will reflect guideline recommendations and HTA findings when available.
Placeholder: When evidence is mixed, prior authorization may require demonstration of expected benefit as defined by trial endpoints and follow‑up measurement plans.
Placeholder: For rehabilitation devices used adjunctively (e.g., PoNS), documentation that the device will be used with supervised therapeutic exercise is required.
Placeholder: Policy reviewers may request device regulatory information, trial data, and practitioner credentialing when evaluating implant requests.
Placeholder: Investigational designations are subject to change as new high‑quality evidence emerges; periodic review of the literature is necessary.
Placeholder: Payers should consider guideline recommendations (e.g., NICE, ASCO) when assessing coverage for specific modalities and indications.
Placeholder: Documentation of functional outcomes (e.g., 6MWT, walking speed, IKES, validated pain/disability scales) supports assessments of clinical benefit.
policy_revision_detail_added
Added detailed NMES coverage criteria identifying proven and medically necessary indications: disuse muscle atrophy with intact nerve supply, as part of comprehensive lower limb rehab after total knee arthroplasty, and to improve upper extremity function after stroke when used within comprehensive rehabilitation.
administrative_update
Added language that medical records documentation may be required and specified documentation elements (relevant history, exam, diagnostic tests), clarified that documentation does not guarantee coverage, and updated applicable codes (removed HCPCS E0762 and revised description for E0721); also updated Description of Services, Clinical Evidence, and References and archived prior version CS036IN.11.